Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:35:20.006Z.
Calculation as of: 2026-10-06T13:35:20.006Z.
Quote observation: 2026-10-06T13:34:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f2d634a7ba4b3af29dc0bd0f7aeccfce6021194a57d8f55324c803ee9ac920cb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Acurx Pharmaceuticals, Inc.
Market Cap
$5.55M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.54M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.31M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.98M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.07M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.97M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acurx Pharmaceuticals, Inc. (ACXP) | $5.55M | N/A | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.54M | N/A | N/A | N/A | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.40M | N/A | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.31M | N/A | N/A | N/A | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.33M | N/A | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $5.21M | N/A | 15.43 | 17.34 | 17.34 |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.98M | N/A | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.07M | N/A | N/A | N/A | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.97M | N/A | N/A | N/A | N/A |
| Femasys Inc. (FEMY)vs › | $6.25M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
